Calidi Biotherapeutics, Inc. (CLDI): R&D Expense
$9.74M
Year ended 2025-12-31
$9.86M
Trailing 12 months to 2026-06-30
+10.3%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.74M | +9.7% | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $8.88M | -31.7% | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | $13.01M | +79.2% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $7.26M | n/a | 2024-03-15, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Calidi Biotherapeutics, Inc. (CLDI) | 2025-12-31 | $9.74M | +9.7% |
| Greenland Mines Ltd (GRML) | 2025-12-31 | $634.2K | n/a |
| Dyadic International Inc (DYAI) | 2025-12-31 | $2.15M | +5.4% |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $2.26M | -5.9% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $4.19M | -16.6% |
| Silexion Therapeutics Corp (SLXN) | 2025-12-31 | $7.14M | +22.8% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $2.37M | -57.2% |
| Exozymes Inc. (EXOZ) | 2025-12-31 | $3.71M | +98.4% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $3.92M | -36.7% |
Compare CLDI, GRML, DYAI, CELZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗